A Study of Tirzepatide (LY3298176) Compared to Dulaglutide in Participants With Type 2 Diabetes
Status:
Completed
Trial end date:
2021-03-31
Target enrollment:
Participant gender:
Summary
The reason for this study is to see if the study drug tirzepatide (LY3298176) is effective
and safe compared to dulaglutide in participants with type 2 diabetes in Japan.
Phase:
Phase 3
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Dulaglutide Immunoglobulin Fc Fragments Tirzepatide